Wednesday, October 14, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 24, 2025

ING Group completes two risk sharing transactions

View original at globenewswire.com
ING Group completes two risk sharing transactions ING Group completes two risk sharing transactions ING Group today announced the successful completion of two significant risk transfer (SRT) transactions, marking the inaugural SRTs for ING Wholesale Banking…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The SRT transactions provide first-loss protection on diversified portfolios of corporate loans with a total notional exposure of €10.5 billion

    80% confidence

  • ING Bank has more than 60,000 employees offering retail and wholesale banking services to customers in over 100 countries

    80% confidence

  • ING's management of ESG material risk is 'Strong' with an ESG risk rating of 18.0 (low risk) as of June 2025

    80% confidence

  • With the SRT transactions, ING strengthens its ability to serve corporate clients by freeing up resources to finance new growth opportunities

    80% confidence

  • ING aims to extend the strategic use of SRTs across Retail and additional Wholesale Banking portfolios in the coming years

    80% confidence

  • The transactions are expected to reduce ING's risk-weighted assets by €3.4 billion, resulting in a pro forma impact of +14 basis points on the 3Q2025 CET1 ratio

    80% confidence

  • The SRT transactions are a milestone in ING's capital velocity strategy, enabled by outstanding teamwork and strong partnerships with leading institutional investors

    80% confidence

  • ING's ESG rating has been upgraded from 'AA' to 'AAA' in October 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
ING Group completes two risk sharing transactions — Source | Via News | Via News